Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...